PatrickHNachmanMDFASN

Glomerular Disease

Professor, Medicine, University of Minnesota. Director, Division of Renal Diseases and Hypertension. Director, Minnesota Multidisciplinary Vasculitis Program

Join to view full profile

Dr. Nachman is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Nachman's full profile

Already have an account?

Office
Division of Nephrology and Hypertension
717 Delaware St. SE
Minneapolis, MN 55414
Phone+1 612-624-9444

Education & Training

University of North Carolina HospitalsFellowship, Nephrology, 1992 - 1996
University of North Carolina HospitalsResidency, Internal Medicine, 1989 - 1992
Boston University School of MedicineClass of 1989

Certifications & Licensure

MN State Medical License 2017 - 2025
NC State Medical License 1991 - 2025
American Board of Internal Medicine Nephrology

Awards, Honors, & Recognition

Fellow (FASN) American Society of Nephrology

Clinical Trials

Rituximab in Progressive Immunoglobulin A (IgA) Nephropathy Start of enrollment: 2009 Feb 01
Completed
Phase 4
Plasma Exchange and Glucocorticoids for Treatment of Anti-Neutrophil Cytoplasm Antibody (ANCA) - Associated Vasculitis Start of enrollment: 2010 May 01
Completed
Phase 3
Nephrotic Syndrome Study Network Start of enrollment: 2010 Apr 01
Recruiting
Targeting Complement Activation in Antineutrophil Cytoplasmic Autoantibodies (ANCA)-Vasculitis - Eculizumab Start of enrollment: 2011 May 01
Withdrawn
Phase 2
Efficacy and Safety of Tolvaptan in Subjects With Chronic Kidney Disease Between Late Stage 2 to Early Stage 4 Due to Autosomal Dominant Polycystic Kidney Disease Start of enrollment: 2014 May 01
Completed
Phase 3
Clinical Trial to Evaluate Safety and Efficacy of CCX168 in ANCA-Associated Vasculitis Start of enrollment: 2015 Feb 04
Completed
Phase 2
Belimumab With Rituximab for Primary Membranous Nephropathy Start of enrollment: 2020 Mar 06
Active, not recruiting
Phase 2
Join now to see all

Publications & Presentations

PubMed

17 citations
Recurrent venous thromboembolism in primary membranous nephropathy despite direct Xa inhibitor therapy.
Monica L. Reynolds, Patrick H. Nachman, Micah J. Mooberry, Daniel J. Crona, Vimal K. Derebail
Journal of Nephrology. 2019-08-01
130 citations
An eQTL Landscape of Kidney Tissue in Human Nephrotic Syndrome.
Christopher E. Gillies, Rosemary K B Putler, Rajasree Menon, Edgar A. Otto, Kalyn Yasutake
American Journal of Human Genetics. 2018-08-02
30 citations
Clinical Characteristics and Treatment Patterns of Children and Adults With IgA Nephropathy or IgA Vasculitis: Findings From the CureGN Study
David T. Selewski, Josephine M. Ambruzs, Gerald B. Appel, Andrew S. Bomback, Raed Bou Matar
Kidney International Reports. 2018-08-03

Lectures

Case Studies in Glomerular Disease
American Society of Nephrology Kidney Week 2019 - Washington, D.C. - 11/9/2019

Authored Content

Repeat Kidney Biopsy for Lupus Nephritis: An Important Step ForwardSeptember 2018

Press Mentions

FDA Panel Endorses Kidney Disease Drug for Serum Phosphorus ControlNovember 17th, 2022
U of M Awarded $2.5M in NIH Funding for Minnesota Site of Kidney Precision Medicine ProjectNovember 3rd, 2022
Sickle Cell Trait Is Not Risk Factor for Kidney Disease: Study Contradicts Earlier FindingsSeptember 14th, 2011
Join now to see all

Grant Support

Clinical Trial: Rituximab In The Treatment Of Idiopathic Membranous NephropathyNational Center For Research Resources2008
Cyclophosphamide-Related Urothelial Tumor EvaluationNational Center For Research Resources2004
Anti-Myeloperoxidase Autoantibody ResponseNational Institute Of Diabetes And Digestive And Kidney Diseases2000–2002
Study To Evaluate The Renal Protective Effects Of LosartanNational Center For Research Resources1998–2002
Molecular Biology Of Antineutrophil Cytoplasmic AutoantibodiesNational Center For Research Resources1998–2002
IDEC-131 In PTS W/ Active Systemic Lupus ErythematosusNational Center For Research Resources2000
H5g1.1-Mab On The Reduction Of Proteinurea In GlomerulopathyNational Center For Research Resources2000
Effects Of Losartan In PTS W/ NIDDM &NephropathyNational Center For Research Resources2000

Committees

Board member, Kidney Health Initial 2020 - Present
Chair, American Society of Nephrology. Post Graduate Education Committee 2015 - 2018
Member, American Society of Nephrology Post Graduate Education Committee 2009 - 2019